Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer
暂无分享,去创建一个
G. Sauter | J. Köllermann | T. Schlomm | C. Bokemeyer | T. Brümmendorf | R. Simon | W. Wilczak | M. Graefen | H. Huland | J. Izbicki | O. Hellwinkel | E. Yekebas | H. Isbarn | J. Zustin | A. T. El Gammal | Michael Brüchmann | J. Schwarz | M. Fisch
[1] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[2] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[3] R. Bookstein,et al. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer , 1994, Genes, chromosomes & cancer.
[4] T. Visakorpi,et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.
[5] T. Hudson,et al. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. , 1996, The American journal of pathology.
[6] D. Schaid,et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. , 1996, Cancer research.
[7] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[8] P. Carroll,et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.
[9] T. H. van der Kwast,et al. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[10] R. Dahiya,et al. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma , 1997, International journal of cancer.
[11] D. Bostwick,et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.
[12] T. Visakorpi,et al. Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.
[13] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.
[14] D. Bostwick,et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.
[15] H. Tanke,et al. Identification of Genetic Markers for Prostatic Cancer Progression , 2000, Laboratory Investigation.
[16] R. Simon,et al. Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.
[17] Y. Kubota,et al. Fluorescence in situ hybridization evaluation of c‐myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients , 2000, The Prostate.
[18] H. Moch,et al. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. , 2000, Urology.
[19] J. Macoska,et al. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. , 2000, Urology.
[20] H. Tanke,et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. , 2001, The American journal of pathology.
[21] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[22] H. Moch,et al. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization * , 2001, The Prostate.
[23] F. Kishi,et al. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. , 2001, Cancer genetics and cytogenetics.
[24] E. Bergstralh,et al. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ‐confined prostate cancer , 2002, Genes, chromosomes & cancer.
[25] M. Graefen,et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.
[26] D. Bostwick,et al. Loss of p53 and c-myc Overrepresentation in Stage T2-3N1-3M0 Prostate Cancer are Potential Markers for Cancer Progression , 2002, Modern Pathology.
[27] T. Mattfeldt,et al. Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization , 2002, BJU international.
[28] K. Pienta,et al. Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.
[29] Ronald Simon,et al. Tissue microarrays in cancer diagnosis , 2003, Expert review of molecular diagnostics.
[30] U. Bergerheim,et al. The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer. , 2003, Aktuelle Urologie.
[31] T. Furuya,et al. DNA sequence copy number aberrations in prostate cancers: a comparison of comparative genomic hybridization data between Japan and European countries. , 2004, Cancer genetics and cytogenetics.
[32] R. Lothe,et al. Genomic analysis of prostate carcinoma specimens obtained via ultrasound‐guided needle biopsy may be of use in preoperative decision‐making , 2004, Cancer.
[33] Holger Sültmann,et al. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. , 2005, International journal of oncology.
[34] K. Das,et al. Chromosomal changes in prostate cancer: A fluorescence in situ hybridization study , 2005, Clinical genetics.
[35] G. Sauter,et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer , 2006, International journal of cancer.
[36] C. Bieberich,et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. , 2006, Cancer research.
[37] R. Lothe,et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis , 2006, Genes, chromosomes & cancer.
[38] A. Chiocchetti,et al. Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7 , 2006, The Prostate.
[39] R. Lothe,et al. 8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects , 2006, Clinical Cancer Research.
[40] A. Haese*,et al. Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.
[41] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[42] Jin Woo Kim,et al. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.
[43] G. Sauter,et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer , 2006, Journal of Clinical Pathology.
[44] R. Henrique,et al. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. , 2007, European urology.
[45] M. Bolla,et al. Guidelines EAU Guidelines on Prostate Cancer , 2007 .
[46] G. Sauter,et al. Molecular staging of prostate cancer in the year 2007 , 2007, World Journal of Urology.
[47] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[48] G. Sauter,et al. Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients , 2008, Clinical Cancer Research.
[49] Martin Schostak,et al. Expression and prognostic relevance of annexin A3 in prostate cancer. , 2008, European urology.
[50] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[51] Michel Bolla,et al. [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.
[52] G. Sauter,et al. Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis , 2009, The Prostate.
[53] John M S Bartlett,et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] T. Furuya,et al. Comparison of chromosomal aberrations between primary tumors and their synchronous lymph-node metastases in intestinal-type gastric carcinoma. , 2009, Pathology, research and practice.